GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Institutional Ownership

GENE (Genetic Technologies) Institutional Ownership : 0.08% (As of Apr. 23, 2025)


View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genetic Technologies's institutional ownership is 0.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genetic Technologies's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genetic Technologies's Float Percentage Of Total Shares Outstanding is 95.79%.


Genetic Technologies Institutional Ownership Historical Data

The historical data trend for Genetic Technologies's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Institutional Ownership Chart

Genetic Technologies Historical Data

The historical data trend for Genetic Technologies can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Genetic Technologies Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Genetic Technologies Business Description

Traded in Other Exchanges
N/A
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.